Guardant Health Non-GAAP EPS of -$0.50 misses by $0.03, revenue of $281.3M beats by $9.02M
Seeking Alpha News (Thu, 19-Feb 4:11 PM ET)
Business Wire (Thu, 19-Feb 4:05 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 19-Feb 10:00 AM ET)
TipRanks (Thu, 19-Feb 9:40 AM ET)
The Week That Was, The Week Ahead: Macro and Markets, Feb. 15
TipRanks (Sun, 15-Feb 4:24 AM ET)
PRNewswire (Thu, 12-Feb 2:35 PM ET)
AI, Genomics, and CRISPR Signal a New Phase of Biological Innovation
Globe Newswire (Tue, 10-Feb 9:29 AM ET)
Guardant Health to Participate in Upcoming Investor Conferences
Business Wire (Tue, 3-Feb 4:05 PM ET)
Business Wire (Mon, 2-Feb 8:05 AM ET)
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Business Wire (Thu, 29-Jan 4:05 PM ET)
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health trades on the NASDAQ stock market under the symbol GH.
As of February 19, 2026, GH stock price declined to $106.38 with 1,528,553 million shares trading.
GH has a beta of 1.08, meaning it tends to be more sensitive to market movements. GH has a correlation of 0.10 to the broad based SPY ETF.
GH has a market cap of $13.82 billion. This is considered a Large Cap stock.
Last quarter Guardant Health reported $265 million in Revenue and -$.39 earnings per share. This beat revenue expectation by $30 million and exceeded earnings estimates by $.22.
In the last 3 years, GH traded as high as $120.74 and as low as $15.81.
The top ETF exchange traded funds that GH belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
GH has outperformed the market in the last year with a price return of +120.4% while the SPY ETF gained +13.1%. GH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +11.3% and +0.2%, respectively, while the SPY returned +4.0% and -0.2%, respectively.
GH support price is $103.47 and resistance is $111.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GH shares will trade within this expected range on the day.
